DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Article Summary
HOLD- Dyne Therapeutics Inc. (Nasdaq: DYN) announced that it has granted inducement equity awards to 12 newly hired employees in accordance with Nasdaq Listing Rule 5635(c)(4) The clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases received non-statutory stock options to purchase up to 358,600 shares of common stock at a per share exercise price equal to closing price of Dyne's common stock on The Nasdaq Global Select Market on July 21, 2026 and restricted stock units with respect to an aggregate of 116,500 shares.
- The stock options have a ten-year term and are scheduled to vest over four years with 25% of the original number of shares vesting on the first anniversary of applicable employee's start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee's continued service to Dyne through applicable vesting dates.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 15.8% | 25% | 50.0 ptsMeets Minimum (15.8%) - Passes screener |
| Target Price Upside ? | 60.9% | 20% | 100.0 ptsMassive Upside (60.9%) - Target: $39.33 vs Current: $24.44 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -2.2% | 15% | 20.0 ptsBarely a Dip (-2.2%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.